Exclusive Domestic Sales Rights Secured for Blood Culture Systems
Priority Negotiation Rights for Exclusive Domestic and International Sales
of Tuberculosis Culture Systems and Molecular Diagnostic Systems
Through this agreement, Dong-A Cham Med has secured exclusive domestic sales rights for blood culture systems such as 'HubCentra FA' and 'HubCentra A'. The company has also obtained the right of first negotiation for exclusive domestic and international sales of upcoming products from Hupeat, including a tuberculosis culture system and molecular diagnostic systems.
Dong-A Cham Med plans to accelerate its entry into the microbial and molecular diagnostics market by leveraging its existing capabilities in in vitro diagnostics and infection control, through this strategic partnership with Hupeat. The two companies also intend to collaborate on joint technology development in the future.
According to reports by global industry and market research organizations such as MarketsandMarkets and The Business Research Company, the global blood culture testing market is projected to reach approximately KRW 5.7 trillion in 2025, while the tuberculosis diagnostics market is expected to reach about KRW 3.5 trillion in 2029. The domestic blood culture testing market is estimated by the industry to be worth around KRW 65 billion.
Hupeat is a company specializing in the diagnosis of infectious diseases. It has developed and distributes blood culture systems 'HubCentra FA' and 'HubCentra A' for sepsis diagnosis. The company is also developing the tuberculosis culture system 'HubCentra TB' and the molecular diagnostic system 'HuPectra', which diagnoses viruses and antibiotic-resistant bacteria.
The blood culture systems 'HubCentra FA' and 'HubCentra A', developed with purely domestic technology, are the first in Korea and the second in the world to feature a fully automated blood culture automation system. Compared to products currently distributed domestically, these systems offer approximately 25% faster detection speed and are characterized by high sensitivity capable of detecting microorganisms at the unit level.
A representative from Dong-A Cham Med stated, "Through this partnership, the addition of Hupeat’s innovative technology to Dong-A Cham Med’s capabilities in in vitro diagnostics and infection control will maximize synergy. We will ensure a stable supply of diagnostic solutions based on domestic technology to the market and further strengthen the competitiveness of both companies."
A Hupeat representative commented, "We have developed the first blood culture system in Korea that matches the performance of global products. At a time when we need marketing and sales partners for a full-scale market entry, this investment and exclusive distribution agreement with Dong-A Cham Med, which has outstanding capabilities and experience, will serve as a turning point for maximizing synergy between the two companies."
Meanwhile, Dong-A Cham Med, a subsidiary of Dong-A ST, is a total medical healthcare specialist company. It operates a medical device division that manufactures, sells, and exports ENT examination devices and medical imaging equipment; an in vitro diagnostics division specializing in consumables for blood collection and in vitro diagnostic medical devices; and an infection control division focused on space disinfection systems, endoscope disinfectors, dedicated disinfectants, and disinfectant wipes.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
